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The promise of cell therapy for repair and restoration of damaged
tissues or organs relies on administration of large dose of cells
whose healing benefits are still limited and sometimes irreproduc-
ible due to uncontrollable cell loss and death at lesion sites. Using
a large amount of therapeutic cells increases the costs for cell
processing and the risks of side effects. Optimal cell delivery strate-
gies are therefore in urgent need to enhance the specificity, efficacy,
and reproducibility of cell therapy leading to minimized cell dosage
and side effects. Here, we addressed this unmet need by developing
injectable 3D microscale cellular niches (microniches) based on bio-
degradable gelatin microcryogels (GMs). The microniches are consti-
tuted by in vitro priming human adipose-derivedmesenchymal stem
cells (hMSCs) seeded within GMs resulting in tissue-like ensembles
with enriched extracellular matrices and enhanced cell–cell interac-
tions. The primed 3D microniches facilitated cell protection from
mechanical insults during injection and in vivo cell retention, sur-
vival, and ultimate therapeutic functions in treatment of critical limb
ischemia (CLI) in mouse models compared with free cell-based ther-
apy. In particular, 3D microniche-based therapy with 105 hMSCs re-
alized better ischemic limb salvage than treatment with 106 free-
injected hMSCs, the minimum dosage with therapeutic effects for
treating CLI in literature. To the best of our knowledge, this is the
first convincing demonstration of injectable and primed cell delivery
strategy realizing superior therapeutic efficacy for treating CLI with
the lowest cell dosage in mouse models. This study offers a widely
applicable cell delivery platform technology to boost the healing
power of cell regenerative therapy.
Cell-based regenerative therapy holds great promise for repairand restoration of damaged tissues or organs with numerous
clinical trials and preclinical animal testing reported for treating
complex diseases (1). Common route of cell administration for
clinical cell therapy is based on either systematic administration
(e.g., i.v. infusion), relying on cells homing to the lesion sites (2),
or direct injection of cells into the damaged tissues (3). However,
therapeutic benefits of the administered cells are still limited and
sometimes irreproducible due to cell loss and cell death (4).
Taking cell therapy for ischemic heart diseases as an example, only
∼5% of mesenchymal stem cells (MSCs) survived after being
transplanted into an infarcted porcine heart (5). Mechanical
damage during injection, high rate of cell loss and leakage to
surrounding tissues, cell death due to lack of appropriate cell–cell
and cell–matrix interactions in the ischemic and inflammatory
lesion tissues could all contribute to poor cell retention, survival,
functionality, and reproducibility of the treatment (6, 7).
A rational solution to enhance the therapeutic efficacy and re-
producibility of cell therapy is to administer a large dose of cells to
ensure sufficient number of functional cells at the lesion sites. Cell
dosage is a primary parameter for clinical cell therapy and in the
case of bone marrow-derived mononuclear cell treatment for
patients with critical limb ischemia (CLI) condition, the dose range
is ∼0.3 ∼ 2 × 109 cells (8). There are several reports to investigate
the effects of cell dosage on therapeutic outcomes in animal
models (9, 10). For instance, injection of 3 × 105 MSCs exhibited
no significant therapeutic angiogenesis in a mouse ischemic limb
model compared with 1 × 106 MSCs, which was shown to be the
minimum dosage with therapeutic effects (11).
Meanwhile, the use of a high dose of cells will not only cost
more for cell processing but also bring uncontrolled risks on safety
due to nonspecific cell incorporation and unwanted influence on
the healthy tissues. For example, in an attempt for treating in-
tervertebral disk degeneration, few injected MSCs were found
within the intervertebral discs (IVDs) after 9 wk, whereas large
anterolateral osteophytes were formed out of the IVDs that were
composed of mineralized tissue surrounded by chondrocytes de-
rived from the injected MSCs indicating potential side effect (12).
The large dose of administered cells also poses higher risks of
uncontrollable cell growth or even tumor genesis, especially when
applying pluripotent stem cell-derived cells (13) or gene-trans-
ferred cells (14).
To improve cell retention, survival, and cell function, pre-
formed cellular aggregates were used to replace disperse cells for
injection-based therapy. However, a large amount of cells is re-
quired to preform the cell aggregates, which usually leads to high
cell consumption, nonuniform size, and uncontrollable aggregate
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numbers (15). Moreover, cell loss in the process of aggregate
formation and mechanical injury to the cells during injection are
still inevitable. Alternatively, biomaterial-assisted cell delivery
approaches have been developed in which responsive bio-
materials (e.g., thermal or pH-sensitive hydrogel) can be coin-
jected with the cells in aqueous form at ambient condition and
cross-linked in situ in the body to realize gelation and cell en-
capsulation (16). However, in situ cross-linked biomaterials such
as hydrogel do not allow priming of cells, which could facilitate
ECM accumulation and cell–cell interactions for construction of
the cellular niche in vitro before transplantation, resulting in
immediate exposure of the delivered cells to ischemic and in-
flammatory microenvironment at the lesion sites. Besides, in situ
gelation and mechanical insult during the injection process
might also cause damage to the encapsulated cells.
Clearly, there is a considerable demand for cell therapy strat-
egies to enhance the specificity, efficacy, and reproducibility of
the administered cells by improving cell engraftment, survival,
and therapeutic functions precisely at the lesion sites leading to
low cell dosage and minimum side effects. The need for targeted
and low-dose cell therapy is analogous to its counterpart in drug-
based therapy, which has been properly addressed by the matu-
ration of drug delivery technologies.
Here, we developed injectable 3D microscale cellular niches
(microniches) as optimal cell delivery and therapy vehicles to meet
the abovementioned unmet need based on biocompatible and
biodegradable gelatin microcryogels (GMs). The injectable 3D
microniches can be constituted by in vitro priming the seeded cells
in theGMs for accumulation of deposited ECMproteins as well as
for enhancing cell–cell interactions. The 3D cellular microniches
result in microscale tissue-like ensembles representing optimal
delivery strategy to facilitate cell protection from mechanical
insults during injection and in vivo cell retention, engraftment,
survival, and the ultimate therapeutic functions at the lesion site.
We chose CLI, one of the most advanced forms of peripheral
artery disease, as a disease model to demonstrate the healing
power of 3D microniche-based cell therapy. To the best of our
knowledge, this is the first systematic and convincing demonstra-
tion of injectable primed 3D cell delivery strategy with superior
therapeutic efficacy and the lowest cell dosage reported so far for
treatment of CLI in mouse models.
Results
Fabrication and Characterization of GMs for Microscale 3D Cell Culture.
GMs were fabricated by cryogelation of gelatin within a micro-
stencil array chip (Movie S1). The harvested GMs exhibited pre-
defined shape and size (Fig. 1A). Interconnected macroporous
structures of GMs were revealed by SEM with pore sizes in the
range of 30–80 μm and porosity of 95.73% ± 0.28% (Fig. 1B and
Fig. S1A). Due to their high porosity, GMs exhibit a relatively high
swelling ratio (23.49 ± 1.57) (Fig. S1A). This feature facilitates cell
loading by automatic absorption of cells into GMs. Moreover,
long-term preservation of the collected GMs can be realized by
vacuum packaging, which can be readily delivered as an off-the-shelf
product to distant users for subsequent cell culture and therapy.
We next examined the biocompatibility of GMs for microscale
3D cell culture. Human adipose-derived MSCs (hMSCs) could
be automatically loaded into GMs by simply pipetting the cells
onto the surface of the collected GMs. Uniform cell distribution,
good cell attachment, and viability were achieved (Fig. 1C).
F-actin filaments of hMSCs were also uniformly formed in GMs
indicating strong cell–matrix interactions (Fig. 1D). The number
of cells loaded in individual GM was controllable from 100 to
1,200 cells per GM by varying the initial cell-loading density (Fig.
S1 C and D). hMSCs in GMs proliferated for at least 4 d re-
gardless of the initial seeding densities (Fig. 1E). The initial cell
seeding density of 8 × 106 cells per mL enabled rapid prolif-
eration resulting in GMs that contained ∼1,000 cells within 2 d,
which was chosen for subsequent experiments.
Injectability of GMs. GMs exhibited a Young’s modulus of 8.25 ±
0.64 kPa, which could be compressed without breaking beyond the
compression limit (i.e., 88.48% ± 2.49% strain, corresponding to
a stress of 61.09 ± 12.75 kPa) achievable by a Bose 3230 me-
chanical testing machine (Fig. S1 A and B). In contrast, gelatin
hydrogel broke with 61.98% ± 2.75% strain, corresponding to
a stress of 32.86 ± 1.67 kPa. The mechanical test clearly demon-
strated the excellent elasticity and deformity of GMs, indicating
their great injectability as optical cell delivery vehicle compared
with hydrogel. Therefore, GMs can provide shielding for cells
frommechanical damage when passing through the needles during
injection.
The injectability of GMs was quantitatively assessed by a pro-
grammable syringe pump integrated with a digital force gauge (7).
GMs suspended in 15% (wt/vol) gelatin carrier solution could be
smoothly injected and remained intact after injection. The force of
injecting GMs with a density of 1,000 per mL at a flow rate of
1 mL/min was below 6 N, which was lower than the clinically ac-
ceptable force of 10 N (7) (Fig. 1F).
hMSCs in GMs could maintain high viability postinjection,
indicating cell protection enabled by GMs (Fig. 1G). Moreover,
hMSCs in GMs subjected to injection maintained great pro-
liferative capacity with ∼800 cells per GM on day 1 and ∼1,300
cells per GM on day 5 (Fig. 1H).
Cell Priming in GMs. As a major component of the microniches,
accumulated ECMs was first investigated, which would be mod-
ulated by the priming duration and relative cell density. Ex-
pression of major ECMs was measured in hMSCs primed in
GMs for 4 h and 2 d (scheme 1) and with low density and high
density (scheme 2) (Fig. 2A). In scheme 1, SEM images revealed
that more deposited ECMs could be observed on the surface of
Fig. 1. Characterization of 3D injectable cellular microniches
based on GMs. (A) Photographs of harvested GMs. (B) SEM
images of GMs showing interconnected and macroporous
structures. (C and D) Fluorescence microscopic and 3D recon-
structed confocal images of GMs autoloaded with hMSCs
stained by live/dead and rhodamine phalloidin. (E) Quanti-
fication of hMSCs autoloading and proliferation in GMs with
different initial loading densities. (F) Real-time injection
force measurement curves for triple injections of 1,000 GMs
in 1 mL of 15% (wt/vol) gelatin solution at 1 mL/min injection
rate (1,000–1–15%). (G) Live/dead cell viability assay of
hMSCs loaded GMs preinjection and postinjection. (H) Pro-
liferation of hMSCs loaded in GMs postinjection after 1, 3,
and 5 d of culture (n = 3).
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cells and macropores for hMSCs primed for 2 d compared with
hMSCs primed for 4 h (Fig. 2B, Left). In quantitative analysis,
hMSCs primed for 2 d expressed significantly higher amount of
collagen I, collagen IV, and laminin (Fig. 2C, Left and Table S1)
compared with those cultured for 4 h. Interestingly, gene expres-
sion of fibronectin was not significantly different with priming
duration potentially due to the lower effectiveness of fibronectin in
stimulating proliferation and differentiation of MSCs (17). In
scheme 2, after 2 d of culture, SEM images revealed that high
density of hMSCs deposited more ECMs on the surface of cells
and macropores compared with the low density of hMSCs in GMs
(Fig. 2B, Right). Moreover, high density of hMSCs in GMs showed
significantly higher expression of collagen I, collagen IV, laminin,
and fibronectin compared with the low-density counterpart
(Fig. 2C, Right).
To further investigate ECM accumulation and enhanced cell–
cell interaction after priming in the microniches, representative
ECMs (i.e., collagen I, collagen IV, laminin, and fibronectin) and
cell adhesion (i.e., E-cadherin) proteins were examined. In scheme
1, expression of collagen I, collagen IV, and laminin in hMSCs
primed for 2 d was significantly higher than those primed for 4 h
(Fig. 2D, Left), whereas expression of fibronectin between the two
groups had no statistical difference, which was consistent with the
gene expression data. Expression of E-cadherin in hMSCs primed
for 2 d was significantly higher than that primed for 4 h. In scheme
2, high density of hMSCs in GMs expressed more collagen I,
collagen IV, laminin, fibronectin, and E-cadherin than the low-
density counterpart (Fig. 2D, Right). Expression of E-cadherin in
high density of hMSCs was significantly higher compared with low
density of hMSCs, indicating enhanced cell–cell interaction. These
results showed that hMSCs primed for 2 d in high density might be
a better priming scheme, which could accumulate abundant ECM
proteins and achieve enhanced cell–cell interaction.
To investigate whether cell priming can promote therapeutic
functions, hMSCs-secreted angiogenic factors (i.e., HGF and
bFGF) were detected in the same two schemes. Similar to the
ECM accumulation, hMSCs primed for 2 d could secrete more
factors than those primed for 4 h and priming in higher density is
preferred, which could significantly increase the factor secretion
compared with priming in low density (Fig. S2). These results
revealed that ECM accumulation and function enhancement
were achieved through the priming process in GMs. More ECM
expression, bioactive factor secretion from primed cells at high
density indicated the importance of targeted cell delivery and
retention to realize cell accumulation at the lesion sites in vivo to
augment therapeutic effect.
Biodegradability of GMs and Enhanced Survival/Retention of hMSCs
Microniches in Mouse Hindlimb. GMs could be degraded in the
presence of trypsin/EDTA solution within 70 min (Fig. S3A).
Moreover, GMs could not be detected 28 d after being injected in
the intramuscular site (Fig. S3B), suggesting good biocompatibility
and biodegradation in vivo.
Strong chemiluminescent signals in vivo were observed in GMs
loaded with hMSCs with minimal diffusion into the surrounding
tissues, whereas the signal was significantly diminished in the free-
cell group 4 d after injection (Fig. 3 B and C). The difference be-
tween the two groups became more significant after 7 d. The signal
was prolonged until 14 d in the mice injected with GMs loaded with
hMSCs, whereas it decreased significantly in the mice injected with
free cells. Semiquantifying the chemiluminescent signals within
regions of interest showed that the survival rate of hMSCs in GMs
was higher than free hMSCs (96.81% ± 3.76% vs. 15.09% ±
0.72% on day 4; 90.44% ± 2.28% vs. 6.13% ± 0.13% on day 7; and
20.30% ± 6.57% vs. 0.20% ± 0.02% on day 14). These results
indicated that the microniche-based delivery could improve
hMSCs retention and survival in vivo after injection, thus
benefiting their therapeutic functions.
Improved Ischemic Limb Salvage. Therapeutic efficacy of the in-
jectable primed hMSCs microniches in limb salvage was exam-
ined by evaluating physiological status of ischemic limbs 28 d
after surgery (Fig. 3A). As shown in the representative photo-
graphs and the corresponding scoring (Fig. 4 A and B and Fig.
S4), no limb salvage was observed in 105 free-cells group (n = 8),
GMs control group (n = 4), or sham group (n = 4). Additionally,
grossly extensive forefoot necrosis was developed at 3 d after
femoral artery ligation, leading to a rate of spontaneous toe
amputation of three of four (75%) within 7 d in both GMs and
sham groups, and finally resulted in complete limb loss for all
experimental mice. The mice treated with 105 free cells had 50%
total toe amputation, 25% partial toe amputation, and 25%
partial limb amputation within 7 d, which finally resulted in 80%
limb loss and 20% total toe amputation after 28 d.
In striking contrast, GMs with primed hMSCs (with total cell
number of 105) achieved limb salvage in six of the eight (75%)
mice, in which four of the six mice completely recovered their
legs and the other two showed minor necrosis. Only two of the
eight (25%) mice showed spontaneous toe amputation. In ad-
dition, the necrotic areas did not expand further during 28 d.
Because 106 hMSCs was previously reported as the minimum
number for effective CLI treatment (11), it was chosen as posi-
tive control. Two of the 106 free hMSCs-treated mice (n = 4)
achieved limb salvage (50%), but all had minor necrosis. One
mouse showed partial toe amputation and the other one showed
total toe amputation. The results further verified the superior
therapeutic effects for CLI treatment achieved by the GMs+
hMSCs, which outperformed the minimum effective dosage for
free cell-based therapy reported so far.
Fig. 2. Cell priming in GMs to constitute the 3D microniches. (A) Two
schemes for priming hMSCs in GMs. (B) SEM images of ECMs of hMSCs in GMs
under two scheme conditions. (C) Gene expression of major ECMs of hMSCs in
GMs under two scheme conditions. (D) Protein expression of representative
ECMs and cell adhesion protein of hMSCs under two scheme conditions. *P <
0.05; **P < 0.01 (n = 3).











Enhanced Angiogenesis in Ischemic Hindlimbs. More extensive micro-
vessel formed around the ligation site of femoral artery on day 28
in the GMs+hMSCs group than the 105 free hMSCs group as well
as other control groups (Fig. 4C). In the 106 free hMSCs group,
sparse vessels could also be observed, but significantly less than the
GMs+hMSCs group. Amazingly, the newly formed vessels in the
GMs+hMSCs group could bridge the gap between the ligation sites
and direct the vessel growth along the native artery.
Immunofluorescent staining and quantification for smooth
muscle α-actin (SMA) (Fig. S5) demonstrated that arteriole for-
mation in 105 free-cell group was comparable to the sham group.
However, the arteriole formation was significantly increased in
those limbs treated with GMs+hMSCs compared with those
treated with 105 free cells. In addition, more extensive immu-
nohistochemical staining of human nuclei antigen was observed
on day 28 in limbs treated with GMs+hMSCs compared with
those treated with 105 free cells (which was largely absent in the
sham group) (Fig. S5), indicating enhanced engraftment and
integration of the transplanted hMSCs in microniches with the
host tissue.
Enhanced Blood Perfusion in Ischemic Hindlimb. To further evaluate
therapeutic angiogenesis in vivo, indocyanine green (ICG), an
angiographic contrast agent that has been Food and Drug
Administration-approved for peripheral vascular imaging (18),
was used as a fluorescent probe to monitor blood perfusion. A
bolus of ICG was injected i.v., and dynamic fluorescence imaging
was carried out immediately after injection on days 0, 3, 7, and 28
(Fig. S6 and Movies S2–S4). As shown in Fig. 5A and Fig. S7, no
fluorescence signal was observed in ischemic hindlimbs of the
mice in all five groups after surgery (day 0), indicating successful
establishment of the ischemic models. Fluorescence signals
appeared in ischemic hindlimbs of the GMs+hMSCs-treated
mice around day 7, and in the 106 free hMSCs-treated mice since
day 14. As expected, no evident fluorescence signal was observed
in the ischemic hindlimbs in the sham or GMs group until day 28.
To obtain more quantitative evaluation, dynamic changes of
average fluorescence intensity after ICG injection in ankle region
of normal and ischemic hindlimbs are plotted simultaneously as
comparison to show the healing process (Fig. 5B). Significant
differences between the two curves were observed in all groups on
day 0, which lasted until day 28 in the sham and GMs group. A
nice correlation between the two curves was observed on day 7 in
the GMs+hMSCs group, which could not be observed until day 28
in the 106 free hMSCs group. Meanwhile, only a slight improve-
ment of correlation was observed in the 105 free hMSCs group.
These results demonstrated enhanced angiogenesis and early
recovery in the GMs+hMSCs-treated ischemic hindlimbs com-
pared with the rest of the treatment strategies. Also, cell dosage
is a determining factor for the therapeutic outcome as indicated
by the drastic differences between the therapeutic effects be-
tween 106 and 105 free hMSCs-treated groups.
Reduced Muscle Degeneration and Fibrosis in Ischemic Hindlimbs.
H&E and Masson’s trichrome staining (Fig. 4D) showed muscle
degeneration and fibrosis in the ischemic regions in the sham group
andGMs group on day 28. Similarly, treatment with 105 free hMSCs
also showed large muscle degeneration and failed to maintain the
large muscle fibrils observed in the normal tissue. In contrast, is-
chemic limbs treated with GMs+hMSCs displayed substantially
reduced tissue degeneration and minimal fibrosis (Fig. 4D).
Enhanced Angiogenesis Factor Expression. Immunohistochemistry
staining showed that expression of angiogenic factor (i.e.,
VEGF, bFGF, and HGF) in the GMs+hMSCs group could be
clearly observed on day 28, whereas expression of these factors
was attenuated in the 105 free-cell group (Fig. 6A). Likewise,
Fig. 3. Bioluminescence imaging (BLI) for tracking cell retention based on
injectable GMs. (A) Schematic of the primed 3D microniches injected into the
mouse hindlimb. (B) Measurement of the average radiance in standardized
regions of interest from hindlimb of mice in different experiment groups on
days 1, 4, 7, and 14. Luminescence signal is presented as photons per second
per square centimeter per steradian (photons/s/cm2/sr). (C) BLI of mice from
different groups for 1, 4, 7, and 14 d (n = 3).
Fig. 4. Improved salvage and enhanced angiogenesis in ischemic hindlimbs
based on the 3D injectable microniches. (A) Representative photographs of
sham (n = 4), blank GMs (n = 4), free hMSCs (105) (n = 8), hMSCs (105) within
GMs (GMs+hMSCs) (n = 8), and free hMSCs (106) (n = 4) at 0, 3, 7, and 28 d
after treatment. (B) Tissue salvage sore of ischemic hindlimbs in different
treatment groups. (C) Photographs showing new vessel formation across
ligation sites of the ischemic hindlimbs 28 d after treatment. (D) H&E
staining and Masson’s trichrome staining of histological ischemic hindlimb
sections 28 d after surgery. Light blue staining for collagen indicates fibrosis
in Masson’s trichrome staining.
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quantitative analysis demonstrated significant increase in pro-
duction of angiogenesis factors in the GMs+hMSCs group
compared with the other three groups (Fig. 6B).
Discussion
Efficacy of current cell therapy for CLI is not satisfactory due to
poor retention, survival, and function of the transplanted cells in
the ischemic and inflammatory lesion sites with only ∼3% cells
being able to play a therapeutic role in the ischemic area (19). In
particular, previous studies revealed the efficacy of cell therapy
for CLI is dosage dependent, which usually required at least 1 ×
106 ∼ 1 × 107 cells to exert significant therapeutic functions, and
1 × 105 cells could not effectively induce therapeutic angiogenesis
in mouse models (11, 20). To improve the efficacy of cell therapy
for CLI, we developed a cell delivery strategy based on primed
3D injectable microniches to achieve superior therapeutic effects
for CLI with cell dosage (1 × 105 cells) 10 times less than the
lowest dosage (1 × 106 cells) used in all previously reported
CLI therapy.
We previously developed injectable microcryogels based on
poly(ethylene glycol-diacrylate) (PEGDA) for cell delivery and
preliminarily proved the enhancement of cell retention and
survival after s.c. injection in mice assisted by the PEGDA
microcryogels (7). Cryogel-based cell delivery has also been de-
veloped by Mooney and colleagues (21, 22), who fabricated
shape-memory millimeter-scale cryogels realizing s.c. injection of
a single-cell–loaded cryogel each time through a 16-gauge nee-
dle. In the present study, we developed biodegradable microscale
gelatin cryogels (GMs) enabling injection of 150 GMs per mouse
using clinically used setting (i.e., 23-gauge needles) for cell
therapy and proved the superior therapeutic efficacy of the 3D
injectable microniches by priming seeded cells within the GMs.
Accumulation of desired ECMs by cells primed in the micro-
niche is the key factor to enhance the therapeutic effect. As the
major component of native cell niches, ECMs can modulate cell
behavior and fate through activating distinct signaling pathways
through biophysical (e.g., surface topography and stiffness) and
biochemical (e.g., growth factors, cytokines) cues (17, 23). There-
fore, mimicry of natural ECMs, provide great opportunity to
maximize the cell function through appropriate cell–cell and cell–
matrix interaction. We believe the microcryogel-based injectable
microniches developed here provide an optimal cell delivery and
therapy platform that equips the cells in vitro for better thera-
peutic functions thanks to the priming process. The primed GMs
constitute biomimetic 3D niches to accumulate ECMs [e.g., col-
lagen I, collagen IV, laminin, and fibronectin (Fig. 2)], which can
increase hMSC viability, proliferation, and differentiation to en-
dothelial cell or smooth muscle cell (17). Moreover, the accu-
mulated ECMs through cell priming within the microniches in
vitro can increase the paracrine secretions of bioactive factors
from the MSCs, such as HGF and bFGF (Fig. S2), which promote
angiogenesis at the lesion sites. In addition, thanks to the excellent
elasticity and accumulated ECMs of the primedmicroniches based
on GMs, hMSCs loaded within GMs could be shielded from the
mechanical insult and necrosis during direct cell injection resulting
in maintained cell viability and functionality.
After cell injection into the lesion site, another challenge is to
prevent the leakage of dispersed cells to surrounding tissues and
maintain cell viability and function. According to a previous
study, acute (<24-h) cell retention of MSCs injected for treating
ischemic diseases was normally less than 10%, regardless of the
delivery route (24). In the present study, we demonstrated the
importance of relative cell density at the lesion site to the overall
therapeutic functions of cells with higher relative density of MSCs
resulting in more ECM production and paracrine secretion of the
bioactive factors (Fig. 2 and Fig. S2). Therefore, it is important to
increase the relative density of cells at the lesion sites for therapy
to establish stronger cell–cell and cell–ECM interactions. In this
work, the primed 3D microniches could realize both long-term
retention and high relative density of cells at the lesion site even
when the total cell dosage was low. Therefore, the microniche-
based delivery strategy greatly improves the cell–cell and cell–
ECM interactions and enhances the cell survival and therapeutic
functions.
Recently, several strategies such as physiological (e.g., hypoxia,
heat shock) and molecular (e.g., cytokine/small molecule) treat-
ment and genetic manipulation are investigated for stem cell
preconditioning in vitro before transplantation in injured (e.g.,
ischemic or fibrotic) tissues (6). For example, preconditioning of
hMSCs with SDF1 for 60 min was shown to enhance their ability
to survive in ischemic myocardium by activation of Akt signaling
pathway, resulting in reduced infarct size and left ventricular
remodeling (25). Preconditioning of hMSCs with a recombinant
Fig. 5. Monitoring blood perfusion in ischemic hindlimb with fluorescence
imaging. (A) Fluorescence images obtained 100 s after ICG injection on days
0, 3, 7, and 28, respectively. (B) Fluorescence intensity–time curves of the
ankle region (indicated by the boxes in the white light images in Fig. S6; red,
normal hindlimb; blue, ischemic hindlimb). Fluorescence intensities were
normalized to the maximal fluorescence intensity in the ankle region of
normal hindlimb. N.F.I., normalized fluorescence intensity.
Fig. 6. Enhanced expression of angiogenic factors in ischemic hindlimbs
treated with the 3D injectable microniches. (A) Immunohistochemical staining
of ischemic muscle tissue sections 28 d after cell therapy for HGF, VEGF, and
bFGF. (B) Images and semiquantitative analysis of Western blot for expressions
of HGF, VEGF, and bFGF of ischemic muscle tissue 28 d after cell therapy. Rel-
ative expression of each protein was normalized to GAPDH, and results of each
group were normalized to the result of the normal group. *P < 0.05 (n = 3).











mixture of growth factors also led to cardiopoietic phenotype and
improved their therapeutic benefit in chronic ischemic cardiomy-
opathy (26). In our study, effect of cell priming on hMSCs dif-
ferentiation was preliminarily investigated, because up-regulated
expression of ECM components was realized in the primed GMs
(Fig. 2 C and D), which could direct the lineage commitment of
hMSCs (17). In particular, laminin shows high affinity to bind αvβ3
integrin/CD61 receptors of hMSCs, which is critical for endothelial
differentiation through activation of VEGFR and PDGFR (27).
Hence we investigated the expression of CD61 in primed hMSCs,
which exhibited significantly higher expression for 2-d priming and
high-density priming compared with the 4-h and low-density
counterparts (Fig. S8B). We further investigated the expression of
forkhead box C1 (FOXC1), an endothelial-specific transcriptional
factor (27), and CD31, an endothelial marker, which showed en-
hanced expression of FOXC1 for 2-d priming and high-density
priming compared with the corresponding counterparts (Fig. S8C).
However, no significant difference in CD31 expression (Fig. S8D)
was observed under current priming conditions (i.e., 4 h vs. 2 d; low
density vs. high density), indicating that only early stage of endo-
thelial differentiation was initiated in the primed hMSCs without
full commitment to endothelial lineage. After primed for 7 d,CD31
expression was highly up-regulated with significant increase com-
pared with 2-d priming, indicating that the primed hMSCs could
differentiate into endothelial lineage after a longer term of priming.
Timing for hMSCs priming is a critical parameter to consider
for optimal therapeutic efficacy. As hMSCs may become sen-
escent (e.g., morphology alteration, declined differentiation po-
tential, and progressive growth arrest) during long-term culture/
expansion in vitro (28), there exists a balance between the ben-
efits in ECM/bioactive factor accumulation and the potential cell
senescence during cell priming. Systematic investigation and
optimization on the priming timing and its influence on cell fate
and therapeutic efficacy of CLI treatment will be the focus of our
future study, which is expected to be vital to fully release the
therapeutic power in regenerative medicine. Meanwhile, we will
explore the possible mechanism and ultimate fate of the trans-
planted cells by tracking the cell location, migration, and dif-
ferentiation at the lesion site.
The ultimate goal of regenerative medicine is to achieve targeted
and high-efficient therapy with minimum dosage and side effects of
the administered cells. It is envisioned that the microniche-assisted
cell therapy system holds great promise to realize this goal as
a widely adopted platform technology.
Materials and Methods
Detailed information is provided in SI Materials and Methods.
GMs (with diameters of 400 μm) were prepared by a microstencil array chip
(75 cm × 25 cm with thickness of 300 μm) (29). Briefly, 6% (wt/vol) gelatin
precursor solution was mixed with 0.3% glutaraldehyde, and then 200 μL of
precursor solution was pipetted and scraped onto the microstencil array chip.
The microstencil array chip underwent cryogelation for 16 h and then was
lyophilized for 30 min (Boyikang). GMs were then harvested by a PMMA
Ejector Pin array fabricated by a desktop 3D milling machine (MDX-40A; Ro-
land DG) (9).
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